

**Nadav Peles**

Co-founder / Acting CEO

Company: **Ta Geza**

TaGeza is a privately held preclinical company dedicated to the study of cancer stem cells in the most malignant and deadliest forms of cancer. TaGeza seeks to identify central markers of highly aggressive cancer stem cells and develop drugs to target this cell population with the goal of eradicating different forms of treatment-resistant cancers as a combination therapy with standard treatments. By using high passage in-vivo expansion of tumor implants, TaGeza's platform enriches the cancer stem cell population, and provides a unique method for the discovery of novel therapeutic targets. Using its cutting-edge technology, as well as its method of in-vivo and in-vitro validation, the company is currently evaluating proprietary target candidates for the development of conjugated antibodies. TaGeza strives to partner with pharma and biotech companies to develop certain targets, and at the same time to build stand-alone capabilities for the development of additional targets.